Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Sign Up to like & getrecommendations! Published in 2021 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2021-003277
Abstract: Background Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these… read more here.
Keywords: vedolizumab; imdc; treatment; efficacy ... See more keywords
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.00320
Abstract: PURPOSE Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI resumption. METHODS This retrospective multicenter study… read more here.
Keywords: therapy; resumption; imdc; immune checkpoint ... See more keywords
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Gastroenterology"
DOI: 10.20524/aog.2022.0722
Abstract: Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but are associated with immune-mediated diarrhea and colitis (IMDC). Clostridioides difficile infection (CDI) can cause infectious diarrhea with overlapping symptoms. Thus, we sought to elucidate the… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; imdc; cancer patients ... See more keywords
Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model
Sign Up to like & getrecommendations! Published in 2019 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2019.967
Abstract: Introduction We evaluated overall survival (OS) benefit of complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) using a propensity score-matched (PSM) analysis to balance groups by age, gender and by the International Metastatic RCC… read more here.
Keywords: renal cell; imdc; prognostic model; complete metastasectomy ... See more keywords